Animal studies have shown that GLP-1 receptor activation may reduce retinal inflammation and oxidative stress
Learn More About Retatrutide What is Retatrutide Retatrutide is a first-in-class synthetic peptide developed by Eli Lilly that simultaneously activates three hormone receptors glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon that together govern appetite, metabolism, insulin sensitivity, energy expenditure, and fat oxidation
Retatrutide has become a major focus in modern metabolic and obesity research
Semaglutide Dosing# FDA-approved dosing with established protocols: Ozempic (T2D) : Start 0.25 mg weekly, escalate to 0.5-2 mg over 8-16 weeks Wegovy (obesity) : Start 0.25 mg weekly, escalate through 0.5, 1.0, 1.7, to 2.4 mg maintenance over 16 weeks Rybelsus (oral T2D) : Start 3 mg daily, escalate to 7-14 mg daily over 30-60 days Semaglutide benefits from established guidelines for missed doses, switching between formulations, special populations (renal/hepatic impairment, elderly), and drug interactions
doi: 10.1016/S0140-6736(21)00213-0 234 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al